Search - tctmd.com

Displaying 1 - 20 of 153

Sort: Relevancy | Date

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

News Conference News VIVA 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

November 05, 2024

‘Unlocking’ Scaffold Matches DES in Wide Range of PCI Patients, Including ACS

News Conference News ESC 2024

‘Unlocking’ Scaffold Matches DES in Wide Range of PCI Patients, Including ACS

Michael O'Riordan

September 09, 2024

DES Best for In-Stent Restenosis, but DCBs Also Viable

News Daily News

DES Best for In-Stent Restenosis, but DCBs Also Viable

Michael O'Riordan

August 13, 2024

Solid 2-Year Data With ‘Unlocking’ Coronary Stent: BIOADAPTOR RCT

News Conference News EuroPCR 2024

Solid 2-Year Data With ‘Unlocking’ Coronary Stent: BIOADAPTOR RCT

Michael O'Riordan

May 28, 2024

FDA Approves Bioresorbable Scaffold for BTK Lesions

News Daily News

FDA Approves Bioresorbable Scaffold for BTK Lesions

Michael O'Riordan

April 29, 2024

Newest Resorbable Magnesium Scaffold Shows Promise in BIOMAG-1

News Conference News EAS 2023

Newest Resorbable Magnesium Scaffold Shows Promise in BIOMAG-1

Michael O'Riordan

May 25, 2023

‘Fascinating’ Unlocking Coronary Stent Prompts Cautious Praise

News Conference News EuroPCR 2023

‘Fascinating’ Unlocking Coronary Stent Prompts Cautious Praise

Michael O'Riordan

May 18, 2023

Shorter DAPT Sufficient Even in Complex HBR Patients: MASTER DAPT

News Conference News EuroPCR 2022

Shorter DAPT Sufficient Even in Complex HBR Patients: MASTER DAPT

Yael L. Maxwell

May 17, 2022

BIOFLOW V: Orsiro Still Offers Some Benefits at 5 Years

News Conference News

BIOFLOW V: Orsiro Still Offers Some Benefits at 5 Years

March 02, 2022

Good Long-term Results With FANTOM BVS, but More Data Needed

News Conference News TCT 2021

Good Long-term Results With FANTOM BVS, but More Data Needed

Michael O'Riordan

October 21, 2021

Title (ideally under 60 characters) DCB Match DES for Treating Coronary In-Stent Restenosis: European Registry

News Daily News

DCB Match DES for Treating Coronary In-Stent Restenosis: European Registry

September 15, 2021

MASTER DAPT: One Month's Enough in Patients at High Bleeding Risk

News Conference News ESC 2021

MASTER DAPT: One Month's Enough in Patients at High Bleeding Risk

August 28, 2021

FUTURE II: A Good ‘First Step’ for Thinner-Strut Bioresorbable Scaffold

News Conference News EuroPCR 2021

FUTURE II: A Good ‘First Step’ for Thinner-Strut Bioresorbable Scaffold

Michael O'Riordan

May 19, 2021

‘Healing’ Stent Noninferior to Permanent-Polymer Device: PIONEER III

News Conference News

‘Healing’ Stent Noninferior to Permanent-Polymer Device: PIONEER III

November 19, 2020

Stent Polymer Face-off Calls Bioresorbable Coatings Into Question

News Conference News TCT 2020

Stent Polymer Face-off Calls Bioresorbable Coatings Into Question

October 17, 2020

TICO: Ticagrelor Monotherapy After 3 Months of DAPT Curbs Bleeding in Stented ACS Patients

News Conference News ACC 2020

TICO: Ticagrelor Monotherapy After 3 Months of DAPT Curbs Bleeding in Stented ACS Patients

March 31, 2020

Newer, Thinner-Strut Abbott Scaffold Prompts Talk of a BVS Comeback

News Conference News CRT 2020

Newer, Thinner-Strut Abbott Scaffold Prompts Talk of a BVS Comeback

Michael O'Riordan

February 28, 2020

BIOFLOW V: Orsiro Bests Xience at 3 Years for TLF, Late Stent Thrombosis

News Conference News CRT 2020

BIOFLOW V: Orsiro Bests Xience at 3 Years for TLF, Late Stent Thrombosis

February 25, 2020

Stent-Related Adverse Events Continue Out to 5 Years: Meta-analysis

News Daily News

Stent-Related Adverse Events Continue Out to 5 Years: Meta-analysis

Michael O'Riordan

February 10, 2020

COMPARE: Similar Efficacy and Safety for Paclitaxel Balloons Regardless of Dose

News Conference News LINC 2020

COMPARE: Similar Efficacy and Safety for Paclitaxel Balloons Regardless of Dose

January 28, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.